摘要
①目的 观察吸入普米克治疗咳嗽变异性哮喘的效果。②方法 将78 例咳嗽变异性哮喘病儿随机分为两组:对照组40例,给予口服美普清和酮替芬,连用3个月;治疗组38 例,给予普米克(布地奈德)及喘康速吸入治疗,待咳嗽明显减轻时,停用喘康速,继续吸入普米克,维持治疗90 d以上。观察用药后1 周、半个月、1 月、3月咳嗽消失的情况。③结果 治疗组显效33例,有效5例,无效0例;对照组显效25例,有效12例,无效3例。两组比较差异有显著性(uc=2.52,P<0.01)。④结论 吸入普米克治疗咳嗽变异性哮喘的效果显著,明显优于口服支气管扩张剂及抗过敏药物。
Objective To assess the effects of inhalation of Pulmicort for cough variant asthma（CVA）. Methods Seventy-eight children with CVA were randomly divided into two groups, control group（n=38） and treated group （n=40）. The children in the control group took Meptin and Ketotifen orally; while those in the treated group inhaled Pulmicort （Budesonide） and Bricasol. When the cough was obviously relieved, Bricasol was withdrawn, but the inhalation of Pulmicort continued for at least 90 days. The complete remission of cough at one week, half a month, one month and three months after the inhalation was recorded. Results In the treated group, marked response in 33 cases, response in five; in the control group, the marked response, response and no response were noted in 25, 12 and three cases, respectively. A significant difference existed between the two groups （uc= 2.52, P〈0.01）. Conclusion Pulmicort inhaled is effective for VCA, it is obviously superior to oral bronehia dilatators and anti-allergic drugs.
出处
《齐鲁医学杂志》
2005年第2期150-151,共2页
Medical Journal of Qilu
